Iovance Biotherapeutics Ownership | Who Owns Iovance Biotherapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Iovance Biotherapeutics Ownership Summary


Iovance Biotherapeutics is owned by 39.30% institutional investors, 0.36% insiders, and 60.34% retail investors. Mhr fund management is the largest institutional shareholder, holding 8.66% of IOVA shares. State Street® SPDR® S&P® Biotech ETF is the top mutual fund, with 2.94% of its assets in Iovance Biotherapeutics shares.

IOVA Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockIovance Biotherapeutics39.30%0.36%60.34%
SectorHealthcare Stocks 231.98%10.74%-142.72%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Mhr fund management28.97M8.66%$62.86M
Blackrock funding, inc. /de29.52M8.11%$80.58M
Blackrock21.23M7.97%$170.23M
Vanguard group27.21M7.47%$74.28M
State street20.16M5.54%$55.04B
Invenomic capital management lp10.54M3.15%$22.88M
Long focus capital management9.12M2.73%$19.78M
Morgan stanley9.19M2.52%$25.09M
Goldman sachs group8.61M2.36%$23.50M
Palo alto investors lp7.62M2.28%$16.53M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Mhr fund management28.97M6.16%$62.86M
Palo alto investors lp7.62M3.06%$16.53M
B group1.50M2.39%$3.25M
Orion investment1.86M1.54%$5.07M
Invenomic capital management lp10.54M1.11%$22.88M
Cm management400.00K0.92%$1.09M
Parametrica management195.88K0.82%$534.75K
Long focus capital management9.12M0.65%$19.78M
Kennondale capital management318.19K0.53%$690.47K
Mirador capital partners lp1.03M0.39%$2.82M

Top Buyers

HolderShares% AssetsChange
State street20.16M0.00%6.85M
Palo alto investors lp7.62M3.06%4.19M
Hrt financial lp4.36M0.04%3.99M
Morgan stanley9.19M0.00%3.61M
Blackrock funding, inc. /de29.52M0.00%3.56M

Top Sellers

HolderShares% AssetsChange
Perceptive advisors---12.71M
Hood river capital management---9.22M
Macquarie group---4.79M
Artisan partners limited partnership---4.41M
Avoro capital advisors---3.50M

New Positions

HolderShares% AssetsChangeValue
Artal group1.01M0.21%1.01M$8.11M
Susquehanna portfolio strategies912.10K0.03%912.10K$1.98M
Norges bank416.24K0.00%416.24K$3.08M
Cinctive capital management lp195.29K0.02%195.29K$423.78K
Neos investment management173.87K0.00%173.87K$377.30K

Sold Out

HolderChange
Nbc securities-4.00
Sjs investment consulting-4.00
Global financial private client-4.00
Global retirement partners-5.00
Capital performance advisors llp-11.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025168-35.63%143,064,086-32.81%390.97%89-29.37%43-41.89%
Sep 30, 20252470.82%212,726,6064.22%631.71%118-4.07%69-1.43%
Jun 30, 2025250-18.03%220,042,797-8.11%651.20%125-19.87%74-16.85%
Mar 31, 202524-92.48%69,746,593-71.12%210.34%12-92.36%4-95.40%
Dec 31, 2024193-35.02%100,034,590-57.33%320.55%92-39.07%50-37.50%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
State Street® SPDR® S&P® Biotech ETF12.11M2.94%-65.18K
Vanguard Total Stock Mkt Idx Inv11.22M2.72%-
Vanguard US Total Market Shares ETF8.71M2.66%762.45K
iShares Russell 2000 ETF7.39M1.79%4.16M
Hood River Small-Cap Growth Instl5.10M1.53%-
Macquarie Small Cap Core I4.08M1.22%56.67K
Invenomic Institutional5.01M1.22%551.34K
SPDR® S&P Biotech ETF3.56M0.98%7.96K
Vanguard Small Cap Index4.05M0.98%-4.99K
Vanguard Institutional Extnd Mkt Idx Tr3.61M0.88%15.83K

Recent Insider Transactions


DateNameRoleActivityValue
Jun 05, 2025Kirby Daniel Gordon Chief Commercial OfficerBuy$55.20K
May 23, 2025Puri Raj K. Chief Regulatory OfficerBuy$9.74K
May 14, 2025Vogt Frederick G Interim CEO & General CounselBuy$42.25K
Nov 12, 2024Maynard Ryan D-Sell$503.00K
Feb 20, 2024MCPEAK MERRILL A-Buy$2.29M

Insider Transactions Trends


DateBuySell
2026 Q1--
2025 Q4--
2025 Q3--
2025 Q23-
2025 Q1--

IOVA Ownership FAQ


Who Owns Iovance Biotherapeutics?

Iovance Biotherapeutics shareholders are primarily institutional investors at 39.30%, followed by 0.36% insiders and 60.34% retail investors. The average institutional ownership in Iovance Biotherapeutics's industry, Biotech Stocks , is 381.47%, which Iovance Biotherapeutics falls below.

Who owns the most shares of Iovance Biotherapeutics?

Iovance Biotherapeutics’s largest shareholders are Mhr fund management (28.97M shares, 8.66%), Blackrock funding, inc. /de (29.52M shares, 8.11%), and Blackrock (21.23M shares, 7.97%). Together, they hold 24.74% of Iovance Biotherapeutics’s total shares outstanding.

Does Blackrock own Iovance Biotherapeutics?

Yes, BlackRock owns 7.97% of Iovance Biotherapeutics, totaling 21.23M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 170.23M$. In the last quarter, BlackRock increased its holdings by 1.3M shares, a 6.50% change.

Who is Iovance Biotherapeutics’s biggest shareholder by percentage of total assets invested?

Mhr fund management is Iovance Biotherapeutics’s biggest shareholder by percentage of total assets invested, with 6.16% of its assets in 28.97M Iovance Biotherapeutics shares, valued at 62.86M$.

Who is the top mutual fund holder of Iovance Biotherapeutics shares?

State Street® SPDR® S&P® Biotech ETF is the top mutual fund holder of Iovance Biotherapeutics shares, with 2.94% of its total shares outstanding invested in 12.11M Iovance Biotherapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools